FDA Exempts Eight More Device Classes From Premarket Notification Requirements

August 21, 2015

Last month FDA published a guidance (titled “Intent to Exempt Certain Unclassified, Class II, and Class I Reserved Medical Devices from Premarket Notification Requirements”) announcing that they would not be enforcing compliance with 510(k) requirements for certain classes of medical devices, and with that announcement they released a list of the 120 exempt classes (full list of exempt device classes here). This meant any devices falling into one of the 120 exempt classes would no longer have to comply with FDA’s premarket notification and review requirements, making it significantly easier to get device(s) on the market faster.

Last week, FDA updated this guidance adding eight additional classes that will no longer be required to comply with the Agency’s premarket notification and review requirements. The additional classes include the following:

Cardiovascular Devices:

  • DTL – Adaptor, Stopcock, Manifold, Fitting, Cardiopulmonary Bypass

Gastroenterology Devices:

  • OCY – Endoscopic Guidewire, Gastroenterology-urology
  • KOE – Dilator, Urethral

General & Plastic Surgical Devices:

  • FTA – Light, Surgical, Accessories

Neurological Devices:

  • GZM – Analyzer, Rigidity
  • GZO – Device, Galavanic Skin Response Measurement
  • HCJ – Device, Skin Potential Measurement

Ophthalmic Devices:

  • HLJ – Ophthalmoscope, Battery Powered

Not sure if your device falls into one of the exempt categories or not? We can help figure it out and achieve a successful outcome with FDA during the entire process of getting your medical device on the market. For more information on our services and how we can help you, please contact us.

Agency Alerts General Regulatory

August 21, 2015

FDA Finalizes the Establishment of the Patient Engagement Advisory Committee

In October 2015 the FDA established its first ever Patient Engagement Advisory Committee (PEAC). This was done as part of the Agency’s 'patient-centric' approach, under which FDA is attempting to...

Read More
Agency Alerts

August 21, 2015

FDA Requests Input on Clinical Outcome Assessments Compendium

On April 1, 2015, FDA held a public workshop entitled, “Clinical Outcomes Assessment Development and Implementation: Opportunities and Challenges.” During the meeting, the Agency provided “updates on...

Read More
Agency Alerts General Regulatory

August 21, 2015

Pre-RFD Process: FDA Introduces New Process to Classify Combination Products

During product development some sponsors struggle to determine how their product will be regulated by the FDA.  Will it be considered a drug, medical device, biologic, or combination product?  Based...

Read More